Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript [Seeking Alpha]
Tenaya Therapeutics, Inc. (TNYA)
Company Research
Source: Seeking Alpha
Michelle Corral - Vice President of Investor Relationship & Corporate Communications Faraz Ali - CEO, Interim Principal Financial Officer & Director Whittemore G. Tingley - Chief Medical Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Michael Ulz - Morgan Stanley, Research Division Sara Nik - H.C. Wainwright & Co, LLC, Research Division Cory Jubinville - LifeSci Capital, LLC, Research Division Samantha Corwin - William Blair & Company L.L.C., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Geulah Livshits - Chardan Capital Markets, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Krista, and I'll be your conference operator today. At this time, I would like to welcome you to the Tenaya Therapeutics Interim Clinical Data for TN-201 Conference Call. [Operator Instructions] I would now like to turn the conference over to Michelle Corr
Show less
Read more
Impact Snapshot
Event Time:
TNYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNYA alerts
High impacting Tenaya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNYA
News
- Tenaya Therapeutics (NASDAQ:TNYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.MarketBeat
- Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic CardiomyopathyGlobeNewswire
- Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 [Yahoo! Finance]Yahoo! Finance
TNYA
Earnings
- 11/10/25 - Beat
TNYA
Sec Filings
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- TNYA's page on the SEC website